Elaine Chang1,2, Srikar R Mapakshi1, Pamela Mbang3, Nader Kim El-Mallawany4, Jennifer R Kramer1,5,6, Donna L White1,5,6,7, Elizabeth Y Chiao1,5,8. 1. Center for Innovation, Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX. 2. Section of Hematology & Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX. 3. Cape Fear Valley Medical Center, Fayetteville, NC. 4. Department of Pediatrics, Baylor College of Medicine, Houston, TX. 5. Cancer Prevention and Population Sciences, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston. 6. Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX. 7. Center for Translational Research in Infectious Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, TX. 8. Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, TX.
Abstract
BACKGROUND: Protease inhibitors (PIs) may inhibit Kaposi sarcoma (KS) carcinogenesis. However, PI-based antiretroviral therapy (ART) is rarely a first-line choice in people living with HIV (PLWH) because of cost and toxicities. This is the first systematic review to assess KS incidence stratified by ART type. METHODS: We searched PubMed to identify original, full research reports of KS incidence in ART-treated adult PLWH, stratified by ART class, published between 1996 and 2017. For overlapping cohorts, we included only the most recent study and supplemented data with earlier relevant analyses. We described study design, sociodemographic characteristics, statistical adjustment factors, and KS incidence. RESULTS: We identified 3 unique retrospective cohort studies, and supplemented one of the studies with results from 6 previous subgroup reports, which included 242,309 PLWH and 3570 incident KS cases. Overall, KS crude incidence decreased by a factor of 10 between untreated and ART-treated PLWH; CD4-adjusted KS incidence decreased by ∼50%, with either non-nucleoside reverse transcriptase inhibitor- or PI-based ART. A single study measured a cumulative dose-/time-dependent effect of ART, which reported a relative risk reduction in only the cohort receiving boosted PI-based ART. Other studies defined ART categories by first-line therapy only. CONCLUSIONS: The risk of incident KS was significantly reduced, regardless of ART class even after adjusting for CD4 count. The quality of evidence (ie, most studies categorizing users by first-line ART) does not permit KS risk reduction comparisons across ART types. Given the limited number and retrospective nature of these studies, prospective data are indicated.
BACKGROUND: Protease inhibitors (PIs) may inhibit Kaposi sarcoma (KS) carcinogenesis. However, PI-based antiretroviral therapy (ART) is rarely a first-line choice in people living with HIV (PLWH) because of cost and toxicities. This is the first systematic review to assess KS incidence stratified by ART type. METHODS: We searched PubMed to identify original, full research reports of KS incidence in ART-treated adult PLWH, stratified by ART class, published between 1996 and 2017. For overlapping cohorts, we included only the most recent study and supplemented data with earlier relevant analyses. We described study design, sociodemographic characteristics, statistical adjustment factors, and KS incidence. RESULTS: We identified 3 unique retrospective cohort studies, and supplemented one of the studies with results from 6 previous subgroup reports, which included 242,309 PLWH and 3570 incident KS cases. Overall, KS crude incidence decreased by a factor of 10 between untreated and ART-treated PLWH; CD4-adjusted KS incidence decreased by ∼50%, with either non-nucleoside reverse transcriptase inhibitor- or PI-based ART. A single study measured a cumulative dose-/time-dependent effect of ART, which reported a relative risk reduction in only the cohort receiving boosted PI-based ART. Other studies defined ART categories by first-line therapy only. CONCLUSIONS: The risk of incident KS was significantly reduced, regardless of ART class even after adjusting for CD4 count. The quality of evidence (ie, most studies categorizing users by first-line ART) does not permit KS risk reduction comparisons across ART types. Given the limited number and retrospective nature of these studies, prospective data are indicated.
Authors: Marc A Kowalkowski; Jennifer R Kramer; Peter R Richardson; Insia Suteria; Elizabeth Y Chiao Journal: Clin Infect Dis Date: 2015-01-13 Impact factor: 9.079
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Sara Lodi; Marguerite Guiguet; Dominique Costagliola; Martin Fisher; Andrea de Luca; Kholoud Porter Journal: J Natl Cancer Inst Date: 2010-05-04 Impact factor: 13.506
Authors: Markus Hecht; Sonja Erber; Thomas Harrer; Hartwig Klinker; Thomas Roth; Hans Parsch; Nora Fiebig; Rainer Fietkau; Luitpold V Distel Journal: PLoS One Date: 2015-06-18 Impact factor: 3.240
Authors: Owen Ngalamika; Sody Munsaka; Salum J Lidenge; John T West; Charles Wood Journal: AIDS Res Hum Retroviruses Date: 2021-02-02 Impact factor: 2.205